Novartis AG
0
0
0%

Analysis

Revenue estimate Current quarter
(Dec 2025)
Next quarter
(Mar 2026)
Current year
(Dec 2025)
Next year
(Dec 2026)
Number of Analysts 5 1 16 13
Avg. estimate 13.70B 13.60B 55.48B 56.73B
Low estimate 13.60B 13.60B 54.40B 54.19B
High estimate 14.04B 13.60B 57.35B 58.31B
Last year sales 13.15B 13.23B 50.32B 55.48B
Sales growth 0.04 0.03 0.10 0.02
Access /revenue_estimate data via our API — starting from the Ultra plan.
EPS revisions Current quarter
(Dec 2025)
Next quarter
(Mar 2026)
Current year
(Dec 2025)
Next year
(Dec 2026)
Up last 7 days 0 0 0 0
Up last 30 days 0 0 0 0
Down last 7 days 0 0 0 0
Down last 30 days 0 0 0 0
Access /eps_revisions data via our API — starting from the Ultra plan.

Analyst ratings

Firm Date Action
Oppenheimer Jun 01, 2023 Downgrade
Wedbush Jan 27, 2017 Downgrade
JMP Securities Oct 17, 2016 Initiates
Wedbush Oct 17, 2016 Initiates
Access /analyst_ratings/light data via our API — starting from the Ultra plan.
Market closed

Exchange is currently closed
Pre-market opens in 25 minutes

07:34
00:00
08:55
17:35
23:59

Trading Hours (Monday - Friday):

Pre-market
08:00 - 08:55
Main market
08:55 - 17:35
Post-market
17:35 - 17:50
All times are displayed in the Europe/Vienna timezone (CET, UTC+01:00).